US Patent

US10849884 — Secnidazole for use in the treatment of bacterial vaginosis

Method of Use · Assigned to Lupin Inc · Expires 2035-09-04 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of secnidazole for the treatment of bacterial vaginosis.

USPTO Abstract

Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).

Drugs covered by this patent

Solosec (SECNIDAZOLE) · Evofem Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3270`	—	Solosec

Patent Metadata

Patent number: US10849884
Jurisdiction: US
Classification: Method of Use
Expires: 2035-09-04
Drug substance claim: No
Drug product claim: Yes
Assignee: Lupin Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.